<DOC>
	<DOCNO>NCT01831531</DOCNO>
	<brief_summary>This trial aim study safety , local control , overall survival S-1 combine radiotherapy patient esophageal squamous cell carcinoma . 105 patient recruited trial .</brief_summary>
	<brief_title>Study S-1 Combination With Radiotherapy Esophageal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>Joined study voluntarily sign informed consent form ; Age ＞75 age 1875 intolerant reject intravenous chemotherapy Both gender Esophageal squamous cell carcinoma confirm pathology Local advance esophageal squamous cell carcinoma ( T24N01M01a , TxN1M01a , TxNxM1a , AJCC 6th ) No radiotherapy , chemotherapy treatment prior enrollment PS ECOG 02 Life expectancy 3 month Hemoglobin（Hb）≥9 g/dL WBC≥3x109/L , Neutrophils ( ANC ) ≥1.5x109/L platelet count ( Pt ) ≥100x 109/L Hepatic function : ALAT ASAT &lt; 2.5 x ULN , TBIL &lt; 1.5 x ULN Renal function : creatinine &lt; 1.5 x ULN No immunodeficiency Use effective contraceptive adult prevent pregnancy . Complete esophageal obstruction Deep esophageal ulcer Esophageal perforation Haematemesis After surgery , exploratory thoracotomy , radiotherapy , chemotherapy , target therapy Other malignant tumor , except skin basal cell carcinoma , cervical carcinoma situ , survive evidence disease 3 year Participation interventional clinical trial within 30 day Pregnant breastfeed woman people birthperiod refused take contraceptive Drug addiction Alcoholism AIDS Uncontrolled seizure psychiatric disease , loss control behavior Patient metastasis lung , liver metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>